Prognostic Value of Baseline and Early Variations of Peripheral Blood Inflammatory Ratios and Their Cellular Components in mRCC Treated With Nivolumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
Front Oncol 2022 Sep 23;12(xx)955501, SE Rebuzzi, A Signori, M Stellato, D Santini, M Maruzzo, U De Giorgi, P Pedrazzoli, L Galli, PA Zucali, E Fantinel, C Carella, G Procopio, M Milella, F Boccardo, L Fratino, R Sabbatini, R Ricotta, S Panni, F Massari, M Sorarù, M Santoni, A Cortellini, V Prati, HJ Soto Parra, F Atzori, M Di Napoli, O Caffo, M Messina, F Morelli, G Prati, F Nolè, F Vignani, A Cavo, G Roviello, MA Llaja Obispo, C Porta, S Buti, G Fornarini, GL BannaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.